Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether pembrolizumab, when given after salvage
surgery, is effective in increasing the time a person with squamous cell cancer of the head
and neck remains disease-free following locoregional disease recurrence.